DYN
Price
$16.52
Change
+$0.10 (+0.61%)
Updated
Jan 16, 11:20 AM (EDT)
Capitalization
2.7B
41 days until earnings call
Intraday BUY SELL Signals
NAMS
Price
$31.71
Change
-$0.12 (-0.38%)
Updated
Jan 16, 11:41 AM (EDT)
Capitalization
3.61B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DYN vs NAMS

Header iconDYN vs NAMS Comparison
Open Charts DYN vs NAMSBanner chart's image
Dyne Therapeutics
Price$16.52
Change+$0.10 (+0.61%)
Volume$1.9K
Capitalization2.7B
NewAmsterdam Pharma
Price$31.71
Change-$0.12 (-0.38%)
Volume$400
Capitalization3.61B
DYN vs NAMS Comparison Chart in %
DYN
Daily Signal:
Gain/Loss:
NAMS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DYN vs. NAMS commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Hold and NAMS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (DYN: $16.42 vs. NAMS: $31.83)
Brand notoriety: DYN and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 57% vs. NAMS: 146%
Market capitalization -- DYN: $2.7B vs. NAMS: $3.61B
DYN [@Biotechnology] is valued at $2.7B. NAMS’s [@Biotechnology] market capitalization is $3.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 1 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • DYN’s FA Score: 1 green, 4 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, DYN is a better buy in the long-term than NAMS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 3 TA indicator(s) are bullish while NAMS’s TA Score has 3 bullish TA indicator(s).

  • DYN’s TA Score: 3 bullish, 6 bearish.
  • NAMS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than DYN.

Price Growth

DYN (@Biotechnology) experienced а -10.08% price change this week, while NAMS (@Biotechnology) price change was -11.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was +4.47%, and the average quarterly price growth was +43.25%.

Reported Earning Dates

DYN is expected to report earnings on Feb 26, 2026.

NAMS is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($3.61B) has a higher market cap than DYN($2.7B). NAMS YTD gains are higher at: -9.265 vs. DYN (-16.053). NAMS has higher annual earnings (EBITDA): -268.03M vs. DYN (-445.29M). DYN has more cash in the bank: 792M vs. NAMS (703M). NAMS has less debt than DYN: NAMS (266K) vs DYN (120M). NAMS has higher revenues than DYN: NAMS (35.2M) vs DYN (0).
DYNNAMSDYN / NAMS
Capitalization2.7B3.61B75%
EBITDA-445.29M-268.03M166%
Gain YTD-16.053-9.265173%
P/E RatioN/AN/A-
Revenue035.2M-
Total Cash792M703M113%
Total Debt120M266K45,113%
TECHNICAL ANALYSIS
Technical Analysis
DYNNAMS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
62%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
47%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
42%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
54%
Advances
ODDS (%)
Bullish Trend 26 days ago
85%
Bullish Trend 9 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 2 days ago
57%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
DYN
Daily Signal:
Gain/Loss:
NAMS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMDRX20.010.19
+0.96%
Hartford Schroders US MidCap Opps SDR
DHPIX16.580.11
+0.67%
Diamond Hill Mid Cap I
FGGBX3.010.02
+0.67%
Templeton Global Dynamic Income R6
TIOVX17.330.06
+0.35%
Nuveen International Opps W
RGLJX29.190.10
+0.34%
American Funds Global Insight R-5E

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
-5.90%
RNA - DYN
63%
Loosely correlated
+0.08%
IDYA - DYN
55%
Loosely correlated
-2.62%
XNCR - DYN
55%
Loosely correlated
-8.58%
SYRE - DYN
53%
Loosely correlated
-0.21%
NRIX - DYN
50%
Loosely correlated
-0.95%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with IMVT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-0.28%
IMVT - NAMS
46%
Loosely correlated
-4.94%
IDYA - NAMS
46%
Loosely correlated
-2.62%
CRNX - NAMS
44%
Loosely correlated
+1.82%
DYN - NAMS
43%
Loosely correlated
-5.90%
ROIV - NAMS
42%
Loosely correlated
-2.14%
More